Sugi Predict

Sugi Predict / Compounds / SCHEMBL1997971

SCHEMBL1997971

SCHEMBL1997971

Fc1cc2[nH]ccc2cc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.50
▸ CTSV O60911 2/20 0.43
▸ CTSL P07711 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ NSD2 O96028 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ RIN1 Q13671 1/20 0.43
▸ NCOR2 Q9Y618 1/20 0.43
▸ BACE1 P56817 1/20 0.42
▸ ENPP2 Q13822 1/20 0.41
▸ STAT3 P40763 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PTGER1 P34995 2/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ SRD5A1 P18405 1/20 0.40
▸ SRD5A2 P31213 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465599 0.94 GPR84 (0.50) GPR84CTSVCTSLL3MBTL1NSD2
SCHEMBL1163147 0.94 GPR84 (0.50) GPR84CTSVCTSLL3MBTL1NSD2
SCHEMBL2077679 0.88 SRD5A1 (0.49) CTSVCTSLL3MBTL1NSD2ABL1
SCHEMBL18593225 0.82 SMN1; SMN2 (0.44) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL188066 0.82 L3MBTL1 (0.50) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL186995 0.82 STAT3 (0.48) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL1777085 0.81 SRD5A1 (0.60) CTSVCTSLSMN1; SMN2SRD5A1SRD5A2
SCHEMBL187757 0.81 SRD5A1 (0.60) CTSVCTSLSMN1; SMN2SRD5A1SRD5A2
SCHEMBL15952312 0.81 SRD5A1 (0.42) CTSVCTSLL3MBTL1NSD2ABL1
SCHEMBL15984768 0.80 ELANE (0.45) L3MBTL1NSD2ABL1PPARGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 — — EP disclosed
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 — — US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 — — US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 — — US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 — — US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 — — US disclosed
CN-101547927-A 8-sulfonyl-l, 3, 4, 8-tetrahydr0-2h- [1, 4] oxazepino [6, 7-e] indole derivatives and their use as 5-ht6 receptor ligands BIOVITRUM AB PUBL (SE) 2009-09-30 — — CN disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 — — EP disclosed
CN-101484420-A Indoles as 5-HT 6 modulators BIOVITRUM AB PUBL (SE) 2009-07-15 — — CN disclosed
EP-2046741-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (publ) (SE) 2009-04-15 — — EP disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 — — EP disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 — — EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 — — US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 — — WO disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 — — US disclosed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 — — WO disclosed
EP-0505322-B1 Aminoguanidines CIBA GEIGY AG (CH) 1998-09-09 — — EP disclosed
US-5510353-A TREATING IRRITABLE BOWEL SYNDROME, GASTROESOPHAGEAL REFLUX DISEASE, CONSTIPATION, MIGRAINE HEADACHES SANDOZ LTD. (CH) 1996-04-23 — — US disclosed
EP-0505322-A1 Aminoguanidines SANDOZ LTD. (CH) 1992-09-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A GPR84 211/4885CTSV 3255/4885CTSL 2336/4885
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A GPR84 162/4885CTSV 2429/4885CTSL 2236/4885
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE S1PR3, S1PR2, S1PR1 GPR84 34/4885CTSV 2418/4885CTSL 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.